Several studies have shown that targeted disruption, deregulation, or altered imprinting of the Igf2r gene leads to increased IGF-II levels [31–33]; thus, the downregulated transcript levels of IGF-II receptors in SSc could be responsible for the increased systemic IGF-II historically observed in SSc patients. This evidence concerns the gene IGF2R and systemic sclerosis.